Targeting T Follicular Helper Cells to Control Humoral Allogeneic Immunity.
Targeting T Follicular Helper Cells to Control Humoral Allogeneic Immunity.
复制标题
DOI：
10.1097/tp.0000000000003776
复制
发表时间：
2021-11-01
期刊：
影响因子：
6.2
通讯作者：
Metes D
中科院分区：
文献类型：
--
作者：
Louis K;Macedo C;Metes D
由抗人类白细胞抗原供体特异性抗体(DSA)和抗体介导的排斥反应(ABMR)驱动的体液同种异体免疫显著阻碍了器官移植后存活时间的延长。尽管T滤泡辅助细胞(TFH)在控制抗体反应中的重要性早已得到证实，但它们在引导DSA生成导致ABMR中的作用直到最近才在器官移植的临床环境中得到重视。在这篇综述中，我们全面总结了目前关于人类TFH细胞及其循环(CTFH)细胞的生物学知识，并描述了它们在推动体液同种异体免疫中的关键作用。此外，我们还讨论了目前的诱导治疗和维持免疫抑制药物以及生物治疗对TFH细胞的内在作用，并提供了TFH细胞生物治疗靶向的未来方向和新的机会，有可能使ABMR的预防和治疗朝着个性化和精确化的方向发展。
Humoral allogeneic immunity driven by anti-HLA donor-specific antibodies (DSAs) and antibody-mediated mediated rejection (ABMR) significantly impede prolonged survival of organ allografts after transplantation. Although the importance of T follicular helper (TFH) cells in controlling antibody responses has been long established, their role in directing DSA generation leading to ABMR was only recently appreciated in the clinical setting of organ transplantation. In this review, we provide a comprehensive summary of the current knowledge on the biology of human TFH cells as well as their circulating (cTFH) counterparts and describe their pivotal role in driving humoral alloimmunity. In addition, we discuss the intrinsic effects of current induction therapies and maintenance immunosuppressive drugs as well as of biotherapies on TFH cells; and provide future directions and novel opportunities of biotherapeutic targeting of TFH cells that have the potential of bringing the prophylactic and curative treatments of ABMR towards personalized and precision medicine.
影响因子：
3.7
作者：
Lee F;Luevano M;Veys P;Yong K;Madrigal A;Shaw BE;Saudemont A
通讯作者：
Saudemont A